secwatch.observer — SEC 8-K summary
======================================

Issuer:     CRESCENT BIOPHARMA, INC. (CBIO)
CIK:        0001253689
Form:       8-K
Filed at:   2026-07-30T11:36:15+00:00
Accession:  0001628280-26-050805
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Crescent Biopharma Q2 net loss $24.8M; cash runway extended to H2 2028 after $143.7M offering
--------------------------------------------------------------------------------

- Net loss $24.8M ($0.74/share) vs $21.8M ($4.93/share) in Q2 2025; R&D expenses rose to $19.4M.
- Cash and equivalents $171.6M; pro forma $305.1M after July 2026 public offering of $143.7M gross proceeds.
- Enrollment progressing in ASCEND Phase 1/2 for CR-001 (PD-1 x VEGF bispecific); proof-of-concept data expected Q1 2027.
- CR-002 (PD-L1 ADC) IND submission mid-2026; global Phase 1/2 trial on track for H2 2026 with data H2 2027.
- CR-003 (ITGB6 ADC) Phase 1/2 ongoing in China; proof-of-concept data expected Q1 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1253689/000162828026050805/0001628280-26-050805-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1253689/000162828026050805/cbio-20260730.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-050805

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer